Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs MadeMed

Two GLP-1 desks, one scoreboard. We put HealthRX and MadeMed head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 8 · Grade B

MadeMed

Visit MadeMed Full brief →

The verdict

Too close to call on the Brief Score.

HealthRX and MadeMed are level at 86/100. The scores won't separate them, so the pick comes down to fit: HealthRX for readers who want an accredited, physician-supervised program with a needle-free oral tablet option on either molecule — and value a legitscript trust signal, while accepting that some tiers are company-stated. MadeMed for readers who want to know the exact cost of a titrated dose before starting, and who intend to climb to a full dose.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
92
Supply Reliability
85
84
Transparency
83
94
Access Breadth
91
76
Clinical Oversight
89
84
Track Record
81
82
HealthRXBrief Score 86 · 86MadeMed

Price, coverage & the tracker

HealthRXMadeMed
Brief Score86/100 (B)86/100 (B)
Semaglutide$189/mo$239/mo injectable · $219/mo sublingual (quarterly)
Tirzepatide$349/mo$399/mo injectable · $299/mo sublingual (quarterly)
CoverageNot publicly listed40 states
Brand-name accessYesCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableStableprice stable

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.